AMLN Amylin Pharmaceuticals, Inc. (MM)

Amylin Pharmaceuticals Names Michael Hanley As Vice President of Discovery Research SAN DIEGO, Oct. 31 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. today announced that Michael Hanley, Ph.D. has joined the Company as Vice President, Discovery Research. Dr. Hanley has served on the Scientific Advisory Board of Amylin since 1992 and for the last six months has served as a senior scientific advisor to the Company. Dr. Hanley will oversee Amylin's discovery research in the areas of research chemistry, in-vivo modeling and cell and molecular biology. "Dr. Hanley brings an outstanding record of accomplishment in academic research and highly relevant experience in the development of research programs for biotechnology organizations," commented Daniel M. Bradbury, Chief Operating Officer for Amylin Pharmaceuticals, Inc. "He has played an important role in guiding and refining the drug discovery capabilities of Amylin since the Company's formation, and we are pleased that he has agreed to lead our internal efforts to expand our pipeline of drug candidates to treat metabolic diseases." From 1981 to 1997, Dr. Hanley held faculty positions at Imperial College, London, the Medical Research Council Laboratories, Cambridge, and the University of California at Davis, where he was Professor of Biological Chemistry. During his academic career, Dr. Hanley conducted extensive research in cell signaling, molecular biology of receptors, and peptide pharmacology. He is widely published and has been an editorial advisor for numerous journals, including the Journal of Biological Chemistry and Molecular and Cellular Endocrinology. Dr. Hanley has served on advisory or review panels for the National Institutes of Health, the Medical Research Council and Wellcome Trust of Great Britain, and for the governments of Australia, Singapore, New Zealand, Hong Kong, Denmark and Japan. From 1997 to 2003, he was a senior consultant for healthcare investors in the venture capital and banking communities and for biotechnology companies such as Cell Therapeutics, Zymogenetics, Elan Pharmaceuticals, and Chiron. Dr. Hanley has also set-up and directed research programs in privately-held start-ups, such as Chemocentryx, PsychoGenics, and most recently Harvard-based Resolvyx Pharmaceuticals. He received a bachelor's degree in Biochemistry and a Ph.D. in Molecular Biology from the University of California, Berkeley. Amylin Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative medicines to improve the lives of people with metabolic diseases. The Company's two late-stage, first-in-class diabetes product candidates -- SYMLIN(R) (pramlintide acetate) and exenatide (synthetic exendin-4) -- are being developed to address the global epidemic of diabetes. Amylin has a strategic alliance with Eli Lilly and Company for the co-development and global commercialization of exenatide, and an extended release formulation, exenatide LAR. Building on its experience in the diabetes field, the Company is developing candidates for cardiovascular disease and obesity by utilizing its research experience with the metabolic properties common to all three conditions. Further information on Amylin and its pipeline in metabolism is available at http://www.amylin.com/ . This press release contains forward-looking statements about Amylin, which involve risks and uncertainties. The Company's actual results could differ materially from those forward-looking statements discussed in this press release due to a number of risks and uncertainties, including risks and uncertainties in the FDA's review process generally, risks and uncertainties that approval by the FDA, if any, may be withheld, delayed and/or limited by indications, risks and uncertainties regarding the drug discovery and development process, and uncertainties regarding the company's ongoing clinical studies of its drug candidates, including SYMLIN(R), exenatide and exenatide LAR. Additional risks and uncertainties are described more fully in the Company's most recently filed SEC documents, such as its Annual Report on Form 10-K for the fiscal year ended December 31, 2002 under the heading "Risk Factors", and its Quarterly Reports on Form 10-Q. DATASOURCE: Amylin Pharmaceuticals, Inc. CONTACT: Mark G. Foletta, Vice President of Finance and Chief Financial Officer, Amylin Pharmaceuticals, Inc., +1-858-552-2200 Web site: http://www.amylin.com/

Copyright